Amendment: SEC Form F-4/A filed by SciSparc Ltd.
$SPRC
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the "Term Sheet") with an Israeli-based pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the "Target Company"). Pursuant to the Term Sheet, NeuroThera will acquire a 55% equity interest in the Target Company from certain selling shareholders of the
TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease ("GERD"). Building on Xylo 's success
TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease ("GERD"). Building on Xylo 's successf
SCHEDULE 13G - SciSparc Ltd. (0001611746) (Subject)
6-K - SciSparc Ltd. (0001611746) (Filer)
424B5 - SciSparc Ltd. (0001611746) (Filer)
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag
SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at
As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a
JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed
SC 13G - SciSparc Ltd. (0001611746) (Subject)
SC 13G - SciSparc Ltd. (0001611746) (Filed by)
SC 13G/A - SciSparc Ltd. (0001611746) (Subject)